PubMed:26685104
Annnotations
PubMed_ArguminSci
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 128-382 | DRI_Background | denotes | Preeclampsia, the development of hypertension and proteinuria or end-organ damage during pregnancy, is a leading cause of both maternal and fetal morbidity and mortality and there are no effective clinical treatments for preeclampsia aside from delivery. |
T2 | 383-532 | DRI_Challenge | denotes | The development of preeclampsia is characterized by maladaptation of the maternal immune system, excessive inflammation, and endothelial dysfunction. |
T3 | 533-703 | DRI_Approach | denotes | We have reported that detection of extracellular RNA by Toll-like receptors (TLRs) 3 and 7 is a key initiating signal that contributes to the development of preeclampsia. |
T4 | 704-1036 | DRI_Background | denotes | PLacental eXpanded (PLX-PAD; Pluristem Therapeutics, Inc., Haifa, Israel) cells are human placenta-derived, mesenchymal-like adherent stromal cells that have anti-inflammatory, pro-angiogenic, cytoprotective, and regenerative properties secondary to paracrine secretion of various molecules in response to environmental stimulation. |
T5 | 1037-1217 | DRI_Challenge | denotes | We hypothesized that PLX-PAD cells would reduce the associated inflammation and tissue damage and lower blood pressure in mice with preeclampsia induced by TLR3 or TLR7 activation. |
T6 | 1218-1566 | DRI_Background | denotes | Injection of PLX-PAD cells on gestational day 14 significantly decreased systolic blood pressure by day 17 in TLR3-induced and TLR7-induced hypertensive mice (TLR3: 144 to 111 mmHg and TLR7: 145 to 106 mmHg; both p<0.05), and also normalized their elevated urinary protein/creatinine ratios (TLR3: 5.68 to 3.72 and TLR7: 5.57 to 3.84; both p<0.05). |
T7 | 1567-1810 | DRI_Background | denotes | Gestational day 17 aortic endothelium-dependent relaxation responses improved significantly in TLR3-induced and TLR7-induced hypertensive mice who received PLX-PAD cells on gestational day 14 (TLR3: 35 to 65% and TLR7: 37 to 63%; both p<0.05). |
T8 | 1811-1978 | DRI_Background | denotes | Additionally, markers of systemic inflammation and placental injury, increased markedly in both groups of TLR-induced hypertensive mice, were reduced by PLX-PAD cells. |
T9 | 1979-2089 | DRI_Background | denotes | Importantly, PLX-PAD cell therapy had no effects on these measures in pregnant control mice or on the fetuses. |
T10 | 2090-2266 | DRI_Outcome | denotes | These data demonstrate that PLX-PAD cell therapy can safely reverse preeclampsia-like features during pregnancy and have a potential therapeutic role in preeclampsia treatment. |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T1 | 0-127 | Sentence | denotes | Human placenta-derived stromal cells decrease inflammation, placental injury, and blood pressure in hypertensive pregnant mice. |
TextSentencer_T2 | 128-382 | Sentence | denotes | Preeclampsia, the development of hypertension and proteinuria or end-organ damage during pregnancy, is a leading cause of both maternal and fetal morbidity and mortality and there are no effective clinical treatments for preeclampsia aside from delivery. |
TextSentencer_T3 | 383-532 | Sentence | denotes | The development of preeclampsia is characterized by maladaptation of the maternal immune system, excessive inflammation, and endothelial dysfunction. |
TextSentencer_T4 | 533-703 | Sentence | denotes | We have reported that detection of extracellular RNA by Toll-like receptors (TLRs) 3 and 7 is a key initiating signal that contributes to the development of preeclampsia. |
TextSentencer_T5 | 704-1036 | Sentence | denotes | PLacental eXpanded (PLX-PAD; Pluristem Therapeutics, Inc., Haifa, Israel) cells are human placenta-derived, mesenchymal-like adherent stromal cells that have anti-inflammatory, pro-angiogenic, cytoprotective, and regenerative properties secondary to paracrine secretion of various molecules in response to environmental stimulation. |
TextSentencer_T6 | 1037-1217 | Sentence | denotes | We hypothesized that PLX-PAD cells would reduce the associated inflammation and tissue damage and lower blood pressure in mice with preeclampsia induced by TLR3 or TLR7 activation. |
TextSentencer_T7 | 1218-1382 | Sentence | denotes | Injection of PLX-PAD cells on gestational day 14 significantly decreased systolic blood pressure by day 17 in TLR3-induced and TLR7-induced hypertensive mice (TLR3: |
TextSentencer_T8 | 1383-1408 | Sentence | denotes | 144 to 111 mmHg and TLR7: |
TextSentencer_T9 | 1409-1515 | Sentence | denotes | 145 to 106 mmHg; both p<0.05), and also normalized their elevated urinary protein/creatinine ratios (TLR3: |
TextSentencer_T10 | 1516-1538 | Sentence | denotes | 5.68 to 3.72 and TLR7: |
TextSentencer_T11 | 1539-1566 | Sentence | denotes | 5.57 to 3.84; both p<0.05). |
TextSentencer_T12 | 1567-1765 | Sentence | denotes | Gestational day 17 aortic endothelium-dependent relaxation responses improved significantly in TLR3-induced and TLR7-induced hypertensive mice who received PLX-PAD cells on gestational day 14 (TLR3: |
TextSentencer_T13 | 1766-1785 | Sentence | denotes | 35 to 65% and TLR7: |
TextSentencer_T14 | 1786-1810 | Sentence | denotes | 37 to 63%; both p<0.05). |
TextSentencer_T15 | 1811-1978 | Sentence | denotes | Additionally, markers of systemic inflammation and placental injury, increased markedly in both groups of TLR-induced hypertensive mice, were reduced by PLX-PAD cells. |
TextSentencer_T16 | 1979-2089 | Sentence | denotes | Importantly, PLX-PAD cell therapy had no effects on these measures in pregnant control mice or on the fetuses. |
TextSentencer_T17 | 2090-2266 | Sentence | denotes | These data demonstrate that PLX-PAD cell therapy can safely reverse preeclampsia-like features during pregnancy and have a potential therapeutic role in preeclampsia treatment. |
T1 | 0-127 | Sentence | denotes | Human placenta-derived stromal cells decrease inflammation, placental injury, and blood pressure in hypertensive pregnant mice. |
T2 | 128-382 | Sentence | denotes | Preeclampsia, the development of hypertension and proteinuria or end-organ damage during pregnancy, is a leading cause of both maternal and fetal morbidity and mortality and there are no effective clinical treatments for preeclampsia aside from delivery. |
T3 | 383-532 | Sentence | denotes | The development of preeclampsia is characterized by maladaptation of the maternal immune system, excessive inflammation, and endothelial dysfunction. |
T4 | 533-703 | Sentence | denotes | We have reported that detection of extracellular RNA by Toll-like receptors (TLRs) 3 and 7 is a key initiating signal that contributes to the development of preeclampsia. |
T5 | 704-1036 | Sentence | denotes | PLacental eXpanded (PLX-PAD; Pluristem Therapeutics, Inc., Haifa, Israel) cells are human placenta-derived, mesenchymal-like adherent stromal cells that have anti-inflammatory, pro-angiogenic, cytoprotective, and regenerative properties secondary to paracrine secretion of various molecules in response to environmental stimulation. |
T6 | 1037-1217 | Sentence | denotes | We hypothesized that PLX-PAD cells would reduce the associated inflammation and tissue damage and lower blood pressure in mice with preeclampsia induced by TLR3 or TLR7 activation. |
T7 | 1218-1382 | Sentence | denotes | Injection of PLX-PAD cells on gestational day 14 significantly decreased systolic blood pressure by day 17 in TLR3-induced and TLR7-induced hypertensive mice (TLR3: |
T8 | 1383-1408 | Sentence | denotes | 144 to 111 mmHg and TLR7: |
T9 | 1409-1515 | Sentence | denotes | 145 to 106 mmHg; both p<0.05), and also normalized their elevated urinary protein/creatinine ratios (TLR3: |
T10 | 1516-1538 | Sentence | denotes | 5.68 to 3.72 and TLR7: |
T11 | 1539-1566 | Sentence | denotes | 5.57 to 3.84; both p<0.05). |
T12 | 1567-1765 | Sentence | denotes | Gestational day 17 aortic endothelium-dependent relaxation responses improved significantly in TLR3-induced and TLR7-induced hypertensive mice who received PLX-PAD cells on gestational day 14 (TLR3: |
T13 | 1766-1785 | Sentence | denotes | 35 to 65% and TLR7: |
T14 | 1786-1810 | Sentence | denotes | 37 to 63%; both p<0.05). |
T15 | 1811-1978 | Sentence | denotes | Additionally, markers of systemic inflammation and placental injury, increased markedly in both groups of TLR-induced hypertensive mice, were reduced by PLX-PAD cells. |
T16 | 1979-2089 | Sentence | denotes | Importantly, PLX-PAD cell therapy had no effects on these measures in pregnant control mice or on the fetuses. |
T17 | 2090-2266 | Sentence | denotes | These data demonstrate that PLX-PAD cell therapy can safely reverse preeclampsia-like features during pregnancy and have a potential therapeutic role in preeclampsia treatment. |
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-127 | Sentence | denotes | Human placenta-derived stromal cells decrease inflammation, placental injury, and blood pressure in hypertensive pregnant mice. |
T2 | 128-382 | Sentence | denotes | Preeclampsia, the development of hypertension and proteinuria or end-organ damage during pregnancy, is a leading cause of both maternal and fetal morbidity and mortality and there are no effective clinical treatments for preeclampsia aside from delivery. |
T3 | 383-532 | Sentence | denotes | The development of preeclampsia is characterized by maladaptation of the maternal immune system, excessive inflammation, and endothelial dysfunction. |
T4 | 533-703 | Sentence | denotes | We have reported that detection of extracellular RNA by Toll-like receptors (TLRs) 3 and 7 is a key initiating signal that contributes to the development of preeclampsia. |
T5 | 704-1036 | Sentence | denotes | PLacental eXpanded (PLX-PAD; Pluristem Therapeutics, Inc., Haifa, Israel) cells are human placenta-derived, mesenchymal-like adherent stromal cells that have anti-inflammatory, pro-angiogenic, cytoprotective, and regenerative properties secondary to paracrine secretion of various molecules in response to environmental stimulation. |
T6 | 1037-1217 | Sentence | denotes | We hypothesized that PLX-PAD cells would reduce the associated inflammation and tissue damage and lower blood pressure in mice with preeclampsia induced by TLR3 or TLR7 activation. |
T7 | 1218-1382 | Sentence | denotes | Injection of PLX-PAD cells on gestational day 14 significantly decreased systolic blood pressure by day 17 in TLR3-induced and TLR7-induced hypertensive mice (TLR3: |
T8 | 1383-1408 | Sentence | denotes | 144 to 111 mmHg and TLR7: |
T9 | 1409-1515 | Sentence | denotes | 145 to 106 mmHg; both p<0.05), and also normalized their elevated urinary protein/creatinine ratios (TLR3: |
T10 | 1516-1538 | Sentence | denotes | 5.68 to 3.72 and TLR7: |
T11 | 1539-1566 | Sentence | denotes | 5.57 to 3.84; both p<0.05). |
T12 | 1567-1765 | Sentence | denotes | Gestational day 17 aortic endothelium-dependent relaxation responses improved significantly in TLR3-induced and TLR7-induced hypertensive mice who received PLX-PAD cells on gestational day 14 (TLR3: |
T13 | 1766-1785 | Sentence | denotes | 35 to 65% and TLR7: |
T14 | 1786-1810 | Sentence | denotes | 37 to 63%; both p<0.05). |
T15 | 1811-1978 | Sentence | denotes | Additionally, markers of systemic inflammation and placental injury, increased markedly in both groups of TLR-induced hypertensive mice, were reduced by PLX-PAD cells. |
T16 | 1979-2089 | Sentence | denotes | Importantly, PLX-PAD cell therapy had no effects on these measures in pregnant control mice or on the fetuses. |
T17 | 2090-2266 | Sentence | denotes | These data demonstrate that PLX-PAD cell therapy can safely reverse preeclampsia-like features during pregnancy and have a potential therapeutic role in preeclampsia treatment. |
T1 | 0-127 | Sentence | denotes | Human placenta-derived stromal cells decrease inflammation, placental injury, and blood pressure in hypertensive pregnant mice. |
T2 | 128-382 | Sentence | denotes | Preeclampsia, the development of hypertension and proteinuria or end-organ damage during pregnancy, is a leading cause of both maternal and fetal morbidity and mortality and there are no effective clinical treatments for preeclampsia aside from delivery. |
T3 | 383-532 | Sentence | denotes | The development of preeclampsia is characterized by maladaptation of the maternal immune system, excessive inflammation, and endothelial dysfunction. |
T4 | 533-703 | Sentence | denotes | We have reported that detection of extracellular RNA by Toll-like receptors (TLRs) 3 and 7 is a key initiating signal that contributes to the development of preeclampsia. |
T5 | 704-1036 | Sentence | denotes | PLacental eXpanded (PLX-PAD; Pluristem Therapeutics, Inc., Haifa, Israel) cells are human placenta-derived, mesenchymal-like adherent stromal cells that have anti-inflammatory, pro-angiogenic, cytoprotective, and regenerative properties secondary to paracrine secretion of various molecules in response to environmental stimulation. |
T6 | 1037-1217 | Sentence | denotes | We hypothesized that PLX-PAD cells would reduce the associated inflammation and tissue damage and lower blood pressure in mice with preeclampsia induced by TLR3 or TLR7 activation. |
T7 | 1218-1382 | Sentence | denotes | Injection of PLX-PAD cells on gestational day 14 significantly decreased systolic blood pressure by day 17 in TLR3-induced and TLR7-induced hypertensive mice (TLR3: |
T8 | 1383-1408 | Sentence | denotes | 144 to 111 mmHg and TLR7: |
T9 | 1409-1515 | Sentence | denotes | 145 to 106 mmHg; both p<0.05), and also normalized their elevated urinary protein/creatinine ratios (TLR3: |
T10 | 1516-1538 | Sentence | denotes | 5.68 to 3.72 and TLR7: |
T11 | 1539-1566 | Sentence | denotes | 5.57 to 3.84; both p<0.05). |
T12 | 1567-1765 | Sentence | denotes | Gestational day 17 aortic endothelium-dependent relaxation responses improved significantly in TLR3-induced and TLR7-induced hypertensive mice who received PLX-PAD cells on gestational day 14 (TLR3: |
T13 | 1766-1785 | Sentence | denotes | 35 to 65% and TLR7: |
T14 | 1786-1810 | Sentence | denotes | 37 to 63%; both p<0.05). |
T15 | 1811-1978 | Sentence | denotes | Additionally, markers of systemic inflammation and placental injury, increased markedly in both groups of TLR-induced hypertensive mice, were reduced by PLX-PAD cells. |
T16 | 1979-2089 | Sentence | denotes | Importantly, PLX-PAD cell therapy had no effects on these measures in pregnant control mice or on the fetuses. |
T17 | 2090-2266 | Sentence | denotes | These data demonstrate that PLX-PAD cell therapy can safely reverse preeclampsia-like features during pregnancy and have a potential therapeutic role in preeclampsia treatment. |
Preeclampsia
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-Preeclampsia-B_T1 | 128-140 | ORPHA:275555 | denotes | Preeclampsia |
PD-Preeclampsia-B_T2 | 349-361 | ORPHA:275555 | denotes | preeclampsia |
PD-Preeclampsia-B_T3 | 402-414 | ORPHA:275555 | denotes | preeclampsia |
PD-Preeclampsia-B_T4 | 690-702 | ORPHA:275555 | denotes | preeclampsia |
PD-Preeclampsia-B_T5 | 1169-1181 | ORPHA:275555 | denotes | preeclampsia |
PD-Preeclampsia-B_T6 | 2158-2170 | ORPHA:275555 | denotes | preeclampsia |
PD-Preeclampsia-B_T7 | 2243-2255 | ORPHA:275555 | denotes | preeclampsia |
Preeclampsia-compare
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-Preeclampsia-B_T1 | 128-140 | ORPHA:275555 | denotes | Preeclampsia |
PD-Preeclampsia-B_T2 | 349-361 | ORPHA:275555 | denotes | preeclampsia |
PD-Preeclampsia-B_T3 | 402-414 | ORPHA:275555 | denotes | preeclampsia |
PD-Preeclampsia-B_T4 | 690-702 | ORPHA:275555 | denotes | preeclampsia |
PD-Preeclampsia-B_T5 | 1169-1181 | ORPHA:275555 | denotes | preeclampsia |
PD-Preeclampsia-B_T6 | 2158-2170 | ORPHA:275555 | denotes | preeclampsia |
PD-Preeclampsia-B_T7 | 2243-2255 | ORPHA:275555 | denotes | preeclampsia |
UBERON-AE
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-UBERON-AE-B_T1 | 6-14 | http://purl.obolibrary.org/obo/UBERON_0001987 | denotes | placenta |
PD-UBERON-AE-B_T2 | 794-802 | http://purl.obolibrary.org/obo/UBERON_0001987 | denotes | placenta |
PD-UBERON-AE-B_T3 | 82-87 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
PD-UBERON-AE-B_T4 | 1141-1146 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
PD-UBERON-AE-B_T5 | 1300-1305 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
PD-UBERON-AE-B_T6 | 197-202 | http://purl.obolibrary.org/obo/UBERON_0000062 | denotes | organ |
PD-UBERON-AE-B_T7 | 465-478 | http://purl.obolibrary.org/obo/UBERON_0002405 | denotes | immune system |
PD-UBERON-AE-B_T8 | 728-731 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T9 | 1062-1065 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T10 | 1235-1238 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T11 | 1727-1730 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T12 | 1968-1971 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T13 | 1996-1999 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T14 | 2122-2125 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T15 | 812-823 | http://purl.obolibrary.org/obo/UBERON_0003104 | denotes | mesenchymal |
PD-UBERON-AE-B_T16 | 1117-1123 | http://purl.obolibrary.org/obo/UBERON_0000479 | denotes | tissue |
PD-UBERON-AE-B_T17 | 1593-1604 | http://purl.obolibrary.org/obo/UBERON_0001986 | denotes | endothelium |
performance-test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-UBERON-AE-B_T1 | 197-202 | http://purl.obolibrary.org/obo/UBERON_0000062 | denotes | organ |
PD-UBERON-AE-B_T2 | 6-14 | http://purl.obolibrary.org/obo/UBERON_0001987 | denotes | placenta |
PD-UBERON-AE-B_T3 | 60-69 | http://purl.obolibrary.org/obo/UBERON_0001987 | denotes | placental |
PD-UBERON-AE-B_T4 | 794-802 | http://purl.obolibrary.org/obo/UBERON_0001987 | denotes | placenta |
PD-UBERON-AE-B_T5 | 1862-1871 | http://purl.obolibrary.org/obo/UBERON_0001987 | denotes | placental |
PD-UBERON-AE-B_T6 | 1117-1123 | http://purl.obolibrary.org/obo/UBERON_0000479 | denotes | tissue |
PD-UBERON-AE-B_T7 | 82-87 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
PD-UBERON-AE-B_T8 | 1141-1146 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
PD-UBERON-AE-B_T9 | 1300-1305 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
PD-UBERON-AE-B_T10 | 465-478 | http://purl.obolibrary.org/obo/UBERON_0002405 | denotes | immune system |
PD-UBERON-AE-B_T11 | 728-731 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T12 | 1062-1065 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T13 | 1235-1238 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T14 | 1727-1730 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T15 | 1968-1971 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T16 | 1996-1999 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T17 | 2122-2125 | http://purl.obolibrary.org/obo/UBERON_2001977 | denotes | PAD |
PD-UBERON-AE-B_T18 | 812-823 | http://purl.obolibrary.org/obo/UBERON_0003104 | denotes | mesenchymal |
PD-UBERON-AE-B_T19 | 1593-1604 | http://purl.obolibrary.org/obo/UBERON_0001986 | denotes | endothelium |